|
New Study May Alleviate Sponsor, Regulator Concerns About Foreign Trials
Drugmakers and regulators can be more confident about the rigor of trial data coming from emerging markets as the quality of studies appears to be on par with trials in more research savvy, developed nations, a new study concludes. No statistically significant difference in data quality was revealed when comparing clinical trial data from such developing regions as India, Eastern Europe, Latin America, Africa and China with data from North America and Western Europe, the study in the July 10 Drug Information Journal found.
Clinical Trials Advisor |
Register Now
Archives